IMMUNOGLOBULIN G1 (134-CYSTEINE,228-VALINE,242-PHENYLALANINE,243-GLUTAMIC ACID,339-SERINE,362-CYSTEINE,374-TRYPTOPHAN), ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN MONOCLONAL MEDI5752 .GAMMA.1-CHAIN), DISULFIDE WITH (122-CYSTEINE,212-VALINE) HUMAN MONOCLONAL MEDI5752 .LAMBDA.-CHAIN, (234->231')(237->234')(362->354') TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (239-PHENYLALANINE,240-GLUTAMIC ACID,336-SERINE,354-CYSTEINE,371-SERINE,373-ALANINE,412-VALINE) ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS MONOCLONAL MEDI5752 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MEDI5752 .KAPPA.-CHAIN
Advanced or Metastatic NSCLC
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1205 Active assets in the Advanced or Metastatic NSCLC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1 (134-CYSTEINE,228-VALINE,242-PHENYLALANINE,243-GLUTAMIC ACID,339-SERINE,362-CYSTEINE,374-TRYPTOPHAN), ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN MONOCLONAL MEDI5752 .GAMMA.1-CHAIN), DISULFIDE WITH (122-CYSTEINE,212-VALINE) HUMAN MONOCLONAL MEDI5752 .LAMBDA.-CHAIN, (234->231')(237->234')(362->354') TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (239-PHENYLALANINE,240-GLUTAMIC ACID,336-SERINE,354-CYSTEINE,371-SERINE,373-ALANINE,412-VALINE) ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS MONOCLONAL MEDI5752 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MEDI5752 .KAPPA.-CHAIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →